• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

EQL Pharma

20.10 SEK-2.19 %24/7 14:48
Less than 1K followers

EQL

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-2.19 %
-20.08 %
-60.67 %
-64.67 %
-65.22 %
-77.96 %
-23.28 %
-43.22 %
+273.97 %

EQL Pharma operates in the pharmaceutical industry and focuses on the development, manufacturing and distribution of generic medicines. The company's products are aimed at healthcare institutions and patients who need cost-effective treatment options. The business is global with a primary presence in Europe, North America and Asia. EQL Pharma was founded in 2006 and is headquartered in Lund, Sweden.

Read more
Market cap
593.55M SEK
Turnover
322.25K SEK
Revenue
432.66M
EBIT %
11.25 %
P/E
47.86
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
7/8
2026

Interim report Q1'27

20/8
2026

General meeting '26

5/11
2026

Interim report Q2'27

Regulatory press release2026-07-24 14:30

EQL Pharma Annual Report 2025/2026

EQL Pharma
Regulatory press release2026-07-24 14:30

EQL Pharma Årsredovisning 2025/2026

EQL Pharma
Regulatory press release2026-07-17 10:15

Notice of annual general meeting in EQL Pharma AB

EQL Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-07-17 10:15

Kallelse till årsstämma i EQL Pharma AB

EQL Pharma
Press release2026-07-15 09:57

EQL Pharma: Mellozzan® (melatonin) godkänt i Kazakstan

EQL Pharma
Press release2026-07-15 09:57

EQL Pharma: Mellozzan® (melatonin) approved in Kazakhstan

EQL Pharma
Press release2026-07-13 14:40

EQL Pharma: Memprex© (metenaminhippurat) licensavtal tecknat med partner för Spanien

EQL Pharma
Press release2026-07-13 14:40

EQL Pharma: Memprex© (methenamine hippurate) license signed with partner for Spain

EQL Pharma
Press release2026-07-10 13:25

Inbjudan till presentation i samband med EQL Pharmas delårsrapport, första kvartalet, 2026/27

EQL Pharma
Press release2026-07-10 13:25

Invitation to presentation in connection with EQL Pharma's interim report, first quarter, 2026/27

EQL Pharma
Press release2026-06-15 11:18

EQL Pharma: Metenaminhippurat (varumärket Cystohipp©) har lanserats i Tyskland

EQL Pharma
Press release2026-06-15 11:18

EQL Pharma: Methenamine hippurate (brand name Cystohipp©) has been launched in Germany

EQL Pharma
Third party research2026-05-15 07:13

EQL Pharma: Kostnaderna tilltar - Analysguiden

EQL Pharma levererade ett nytt försäljningsrekord under det fjärde kvartalet, men kvartalet präglades samtidigt av pressade marginaler, leveransproblem och ökade logistikkostnader. Flera engångsposter och en svagare guidning framåt gör att tillväxtcaset...

EQL Pharma
Press release2026-05-13 11:20

Analysguiden: ANALYS EQL Pharma: Kostnaderna tilltar

EQL Pharma
Press release2026-05-13 09:00

Kalqyl: EQL Pharma: Rapportkommentar Q4'25/26

EQL Pharma
Press release2026-05-12 13:45

Kalqyl: EQL Pharma: VD-intervju med Axel Schörling om Q4'25/26

EQL Pharma
Press release2026-05-11 07:16

DNB Carnegie Access: EQL Pharma: Near-term reset; solid execution needed to rebuild the case

EQL Pharma
Press release2026-05-08 09:17

DNB Carnegie Access: EQL Pharma: Better-than-feared Q4 overshadowed by cautious outlook

EQL Pharma
Regulatory press release2026-05-08 07:00

Bokslutskommuniké april 2025 - mars 2026

EQL Pharma
Regulatory press release2026-05-08 07:00

Year-end Report April 2025 - March 2026

EQL Pharma